Antonio Phillips, MD
Family Medicine · Columbus, OHNPI 1679684344
Payments from drug & device makers
Across 647 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- AstraZeneca$1K
- Pfizer$828
- GSK$828
- AbbVie$711
- Novo Nordisk$666
- plus $5K from 33 others
What the payments were for
- Travel & lodging$60%
- Food & beverage$10,446100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 83 | $1,652 |
| AstraZeneca | 75 | $1,192 |
| Pfizer | 52 | $828 |
| GSK | 63 | $828 |
| AbbVie(2 entities) | 62 | $711 |
| Novo Nordisk | 48 | $666 |
| Boehringer Ingelheim | 36 | $651 |
| Merck | 48 | $579 |
| Dexcom, Inc. | 22 | $430 |
| Nevro Corp. | 10 | $344 |
| Astellas Pharma US Inc | 13 | $328 |
| Sanofi-aventis U.S. LLC | 14 | $239 |
| Novartis | 17 | $238 |
| Exact Sciences | 10 | $219 |
| Esperion Therapeutics, Inc. | 8 | $204 |
| Johnson & Johnson | 14 | $188 |
| Ironwood Pharmaceuticals, Inc | 9 | $163 |
| Amgen | 9 | $135 |
| Abbott | 7 | $126 |
| Circassia Inc. | 6 | $107 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Biohaven Pharmaceuticals, Inc. | 3 | $45 |
| Currax Pharmaceuticals LLC | 4 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $33 |
| UCB, Inc. | 2 | $32 |
| Bayer | 2 | $31 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Sunovion Pharmaceuticals Inc. | 3 | $23 |
| Endo Pharmaceuticals Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Redhill Biopharma Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Pulmonx Corporation | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,465 in reported general payments places this provider in the 90th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $114,441 |
| JardianceEmpagliflozin | 145 | $108,358 |
| TrulicityDulaglutide | 91 | $88,711 |
| OzempicSemaglutide | 49 | $51,078 |
| FarxigaDapagliflozin Propanediol | 59 | $49,707 |
| MounjaroTirzepatide | 29 | $45,042 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $22,923 |
| LinzessLinaclotide | 36 | $21,418 |
| EliquisApixaban | 38 | $20,793 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 36 | $20,362 |
| XareltoRivaroxaban | 17 | $19,612 |
| JanuviaSitagliptin Phosphate | 38 | $19,398 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $18,543 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $15,147 |
| MyrbetriqMirabegron | 29 | $13,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Incruse Ellipta | $828 | $150,661210 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $651 | $139,690191 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,652 | $133,752120 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,192 | $82,637128 claims |
| Novo NordiskOzempic | $666 | $51,07849 claims |
| AbbVieLinzess | $711 | $21,41836 claims |
| PfizerEliquis | $828 | $20,79338 claims |
| Johnson & JohnsonXarelto | $188 | $19,61217 claims |
| MerckJanuvia | $579 | $19,39838 claims |
| Astellas Pharma US IncMyrbetriq | $328 | $13,26529 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Columbus
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
- Robert FloreaColumbus$955K
- Bryan FeldmanColumbus$404K
- Scott MerrymanColumbus$89K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.